Trv Gp Vi LLC Takes Position in Rapport Therapeutics, Inc. $RAPP

Key Points

• Trv Gp Vi LLC acquired 969,218 shares of Rapport Therapeutics in the second quarter, valued at approximately $40.4 billion as reported, representing 2.02% of the company and 17.4% of the investor’s portfolio.
• Analysts remain broadly positive, with a consensus “Buy” rating and an average price target of $62.86. Recent targets include $75 from Raymond James, $65 from BTIG Research and $52 from Leerink Partners.
• RAPP shares opened at $49.01, near their 52-week high of $49.50, but the company reported a quarterly loss of $1.19 per share, missing estimates of $1.12; insiders have sold about 72,281 shares worth $3.27 million over the past three months.

Trv Gp Vi LLC purchased a new stake in Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 969,218 shares of the company's stock, valued at approximately $40,387,314,000. Rapport Therapeutics makes up 17.4% of Trv Gp Vi LLC's investment portfolio, making the stock its 3rd largest holding. Trv Gp Vi LLC owned 2.02% of Rapport Therapeutics at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Rapport Therapeutics by 86.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company's stock valued at $99,000 after buying an additional 4,582 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC acquired a new position in shares of Rapport Therapeutics during the first quarter valued at $2,039,000. Rhumbline Advisers lifted its stake in shares of Rapport Therapeutics by 40.1% during the first quarter. Rhumbline Advisers now owns 14,358 shares of the company's stock valued at $144,000 after acquiring an additional 4,109 shares during the period. Geode Capital Management LLC boosted its holdings in Rapport Therapeutics by 5.5% in the second quarter. Geode Capital Management LLC now owns 333,159 shares of the company's stock valued at $3,789,000 after acquiring an additional 17,496 shares during the last quarter. Finally, Creative Planning acquired a new stake in Rapport Therapeutics in the second quarter worth about $121,000.

Insiders Place Their Bets

In other news, CEO Abraham Ceesay sold 28,958 shares of Rapport Therapeutics stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $48.01, for a total transaction of $1,390,273.58. Following the transaction, the chief executive officer directly owned 486,108 shares of the company's stock, valued at $23,338,045.08. This trade represents a 5.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Rock Ventures V. L.P. Third sold 18,572 shares of the business's stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $40.05, for a total transaction of $743,808.60. Following the completion of the transaction, the insider directly owned 6,280,525 shares of the company's stock, valued at $251,535,026.25. This trade represents a 0.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 72,281 shares of company stock worth $3,269,892. Insiders own 12.48% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on RAPP shares. Raymond James Financial restated a "strong-buy" rating and set a $75.00 target price on shares of Rapport Therapeutics in a research report on Monday. Leerink Partners began coverage on shares of Rapport Therapeutics in a report on Wednesday, June 24th. They issued an "outperform" rating and a $52.00 price objective on the stock. BTIG Research reaffirmed a "buy" rating and issued a $65.00 price objective on shares of Rapport Therapeutics in a research note on Wednesday, August 5th. Citigroup reiterated a "market outperform" rating on shares of Rapport Therapeutics in a research report on Tuesday, June 2nd. Finally, UBS Group restated a "strong-buy" rating on shares of Rapport Therapeutics in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Rapport Therapeutics has an average rating of "Buy" and a consensus target price of $62.86.

Rapport Therapeutics Price Performance

Shares of RAPP stock opened at $49.01 on Wednesday. The stock has a market cap of $2.35 billion, a PE ratio of -16.12 and a beta of 0.97. The stock has a 50-day moving average of $41.39 and a 200-day moving average of $35.65. Rapport Therapeutics, Inc. has a one year low of $13.86 and a one year high of $49.50.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.07). As a group, research analysts anticipate that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current year.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.

Want to see what other hedge funds are holding RAPP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source